Despite the improvement in the clinical outcome following the development of molecular targeted therapy against the epidermal growth factor receptor (EGFR) [2], CRC with mutations of BRAF, RAS, PI3K or PTEN are resistant to anti-EGFR therapy [3, 4]. Here, EGFR is linked to colorectal carcinoma.